Recommendations Concerning the Therapeutic Approach to Immunocompromised Children with Tuberculosis

Laura Lancella, Luisa Galli, Elena Chiappini, Carlotta Montagnani, Clara Gabiano, Silvia Garazzino, Nicola Principi, Marina Tadolini, Alberto Matteelli, Giovanni Battista Migliori, Alberto Villani, Maurizio De Martino, Susanna Esposito

Research output: Contribution to journalArticle

Abstract

Purpose This article describes the recommendations of a group of scientific societies concerning the therapeutic approach to immunocompromised children with tuberculosis (TB). Methods Using the Consensus Conference method, relevant publications in English were identified by a systematic review of MEDLINE and the Cochrane Database of Systematic Reviews from their inception until December 31, 2014. Findings On the basis of their clinical experience and the published evidence, the group of experts concluded that, although immunosuppressed subjects are at greater risk of developing TB, none of the signs or symptoms is sensitive or specific enough to enable a diagnosis. Immunocompromised patients are at greater risk of developing extrapulmonary forms of TB, especially if they are adolescents, whereas pulmonary forms are more prevalent among younger patients. When TB is suspected, a combination of skin and immunologic tests and other clinical, radiologic, and microbiologic examinations can be used to assess the risk of infection or disease. If the TB diagnosis is confirmed, immunocompromised children should be treated by using a standard regimen with a minimum of 4 drugs for at least 9 to 12 months, during which the tolerability of the drugs and their interactions should be carefully evaluated. Implications It is difficult to diagnose and treat TB in immunocompromised children. Thus, all pediatric patients undergoing immunosuppressive therapy who develop TB should be diagnosed and treated at a TB reference center, which should also be responsible for the recommended follow-up.

Original languageEnglish
Pages (from-to)180-190
Number of pages11
JournalClinical Therapeutics
Volume38
Issue number1
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Tuberculosis
Therapeutics
Immunologic Tests
Immunocompromised Host
Immunosuppressive Agents
Skin Tests
Drug Interactions
MEDLINE
Signs and Symptoms
Publications
Databases
Pediatrics
Lung
Infection
Pharmaceutical Preparations

Keywords

  • HIV
  • immunodeficiency
  • immunosuppressants
  • Key words children
  • TB
  • tuberculosis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Recommendations Concerning the Therapeutic Approach to Immunocompromised Children with Tuberculosis. / Lancella, Laura; Galli, Luisa; Chiappini, Elena; Montagnani, Carlotta; Gabiano, Clara; Garazzino, Silvia; Principi, Nicola; Tadolini, Marina; Matteelli, Alberto; Migliori, Giovanni Battista; Villani, Alberto; De Martino, Maurizio; Esposito, Susanna.

In: Clinical Therapeutics, Vol. 38, No. 1, 01.01.2016, p. 180-190.

Research output: Contribution to journalArticle

Lancella, L, Galli, L, Chiappini, E, Montagnani, C, Gabiano, C, Garazzino, S, Principi, N, Tadolini, M, Matteelli, A, Migliori, GB, Villani, A, De Martino, M & Esposito, S 2016, 'Recommendations Concerning the Therapeutic Approach to Immunocompromised Children with Tuberculosis', Clinical Therapeutics, vol. 38, no. 1, pp. 180-190. https://doi.org/10.1016/j.clinthera.2015.10.012
Lancella, Laura ; Galli, Luisa ; Chiappini, Elena ; Montagnani, Carlotta ; Gabiano, Clara ; Garazzino, Silvia ; Principi, Nicola ; Tadolini, Marina ; Matteelli, Alberto ; Migliori, Giovanni Battista ; Villani, Alberto ; De Martino, Maurizio ; Esposito, Susanna. / Recommendations Concerning the Therapeutic Approach to Immunocompromised Children with Tuberculosis. In: Clinical Therapeutics. 2016 ; Vol. 38, No. 1. pp. 180-190.
@article{b42312738d3e4591812dfb04c99ac219,
title = "Recommendations Concerning the Therapeutic Approach to Immunocompromised Children with Tuberculosis",
abstract = "Purpose This article describes the recommendations of a group of scientific societies concerning the therapeutic approach to immunocompromised children with tuberculosis (TB). Methods Using the Consensus Conference method, relevant publications in English were identified by a systematic review of MEDLINE and the Cochrane Database of Systematic Reviews from their inception until December 31, 2014. Findings On the basis of their clinical experience and the published evidence, the group of experts concluded that, although immunosuppressed subjects are at greater risk of developing TB, none of the signs or symptoms is sensitive or specific enough to enable a diagnosis. Immunocompromised patients are at greater risk of developing extrapulmonary forms of TB, especially if they are adolescents, whereas pulmonary forms are more prevalent among younger patients. When TB is suspected, a combination of skin and immunologic tests and other clinical, radiologic, and microbiologic examinations can be used to assess the risk of infection or disease. If the TB diagnosis is confirmed, immunocompromised children should be treated by using a standard regimen with a minimum of 4 drugs for at least 9 to 12 months, during which the tolerability of the drugs and their interactions should be carefully evaluated. Implications It is difficult to diagnose and treat TB in immunocompromised children. Thus, all pediatric patients undergoing immunosuppressive therapy who develop TB should be diagnosed and treated at a TB reference center, which should also be responsible for the recommended follow-up.",
keywords = "HIV, immunodeficiency, immunosuppressants, Key words children, TB, tuberculosis",
author = "Laura Lancella and Luisa Galli and Elena Chiappini and Carlotta Montagnani and Clara Gabiano and Silvia Garazzino and Nicola Principi and Marina Tadolini and Alberto Matteelli and Migliori, {Giovanni Battista} and Alberto Villani and {De Martino}, Maurizio and Susanna Esposito",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.clinthera.2015.10.012",
language = "English",
volume = "38",
pages = "180--190",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica Inc.",
number = "1",

}

TY - JOUR

T1 - Recommendations Concerning the Therapeutic Approach to Immunocompromised Children with Tuberculosis

AU - Lancella, Laura

AU - Galli, Luisa

AU - Chiappini, Elena

AU - Montagnani, Carlotta

AU - Gabiano, Clara

AU - Garazzino, Silvia

AU - Principi, Nicola

AU - Tadolini, Marina

AU - Matteelli, Alberto

AU - Migliori, Giovanni Battista

AU - Villani, Alberto

AU - De Martino, Maurizio

AU - Esposito, Susanna

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Purpose This article describes the recommendations of a group of scientific societies concerning the therapeutic approach to immunocompromised children with tuberculosis (TB). Methods Using the Consensus Conference method, relevant publications in English were identified by a systematic review of MEDLINE and the Cochrane Database of Systematic Reviews from their inception until December 31, 2014. Findings On the basis of their clinical experience and the published evidence, the group of experts concluded that, although immunosuppressed subjects are at greater risk of developing TB, none of the signs or symptoms is sensitive or specific enough to enable a diagnosis. Immunocompromised patients are at greater risk of developing extrapulmonary forms of TB, especially if they are adolescents, whereas pulmonary forms are more prevalent among younger patients. When TB is suspected, a combination of skin and immunologic tests and other clinical, radiologic, and microbiologic examinations can be used to assess the risk of infection or disease. If the TB diagnosis is confirmed, immunocompromised children should be treated by using a standard regimen with a minimum of 4 drugs for at least 9 to 12 months, during which the tolerability of the drugs and their interactions should be carefully evaluated. Implications It is difficult to diagnose and treat TB in immunocompromised children. Thus, all pediatric patients undergoing immunosuppressive therapy who develop TB should be diagnosed and treated at a TB reference center, which should also be responsible for the recommended follow-up.

AB - Purpose This article describes the recommendations of a group of scientific societies concerning the therapeutic approach to immunocompromised children with tuberculosis (TB). Methods Using the Consensus Conference method, relevant publications in English were identified by a systematic review of MEDLINE and the Cochrane Database of Systematic Reviews from their inception until December 31, 2014. Findings On the basis of their clinical experience and the published evidence, the group of experts concluded that, although immunosuppressed subjects are at greater risk of developing TB, none of the signs or symptoms is sensitive or specific enough to enable a diagnosis. Immunocompromised patients are at greater risk of developing extrapulmonary forms of TB, especially if they are adolescents, whereas pulmonary forms are more prevalent among younger patients. When TB is suspected, a combination of skin and immunologic tests and other clinical, radiologic, and microbiologic examinations can be used to assess the risk of infection or disease. If the TB diagnosis is confirmed, immunocompromised children should be treated by using a standard regimen with a minimum of 4 drugs for at least 9 to 12 months, during which the tolerability of the drugs and their interactions should be carefully evaluated. Implications It is difficult to diagnose and treat TB in immunocompromised children. Thus, all pediatric patients undergoing immunosuppressive therapy who develop TB should be diagnosed and treated at a TB reference center, which should also be responsible for the recommended follow-up.

KW - HIV

KW - immunodeficiency

KW - immunosuppressants

KW - Key words children

KW - TB

KW - tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=84954362626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954362626&partnerID=8YFLogxK

U2 - 10.1016/j.clinthera.2015.10.012

DO - 10.1016/j.clinthera.2015.10.012

M3 - Article

VL - 38

SP - 180

EP - 190

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 1

ER -